Journal of Allergy and Clinical Immunology-In Practice最新文献

{"title":"Reply to “Correspondence on ‘Neuropsychiatric events related to montelukast and pranlukast in adults with asthma and rhinitis: a 10-year nationwide population-based study’”","authors":"Hyouk-Soo Kwon MD, PhD , Young-Woo Jo PhD , Joonhong Min MD , Young Her MD, PhD , Jae-Woo Kwon MD, PhD","doi":"10.1016/j.jaip.2025.06.017","DOIUrl":"10.1016/j.jaip.2025.06.017","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Page 2535"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Diagnosis and Treatment in Chronic Spontaneous and Inducible Urticaria: Advances, Gaps, and the Future of Personalized Care","authors":"L. Karla Arruda MD, PhD , Jonathan A. Bernstein MD","doi":"10.1016/j.jaip.2025.07.031","DOIUrl":"10.1016/j.jaip.2025.07.031","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2287-2289"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of Egg Sensitization in Pediatric Food Protein–Induced Enterocolitis Syndrome to Hen’s Egg","authors":"Alexandra Navard-Keck MD ,&nbsp;Samantha Horn MD ,&nbsp;Terri F. Brown-Whitehorn MD ,&nbsp;Melanie A. Ruffner MD, PhD ,&nbsp;Pooja Varshney MD","doi":"10.1016/j.jaip.2025.05.055","DOIUrl":"10.1016/j.jaip.2025.05.055","url":null,"abstract":"<div><h3>Background</h3><div>Hen’s egg, a common IgE-mediated food allergen<span>, is an increasingly common food protein–induced enterocolitis syndrome (FPIES) trigger. Atypical FPIES is defined as detectable IgE to the food causing FPIES.</span></div></div><div><h3>Objective</h3><div>To evaluate clinical characteristics, natural history, baked egg tolerance, and FPIES challenge outcomes based on allergic sensitization status in patients with egg FPIES.</div></div><div><h3>Methods</h3><div>This retrospective, dual-center cohort study examined children with the diagnosis of egg FPIES by an allergist. We reviewed charts for reaction characteristics, atopic history, allergic sensitization to egg, baked egg tolerance, and food reintroduction outcomes.</div></div><div><h3>Results</h3><div>Of 153 patients with FPIES, 124 underwent egg allergy<span> testing and 56 (36.6%) were sensitized to egg. Skin testing and food reintroduction varied based on practice and patient preferences. Of 48 patients who introduced baked egg, 30 (62.5%) tolerated it after a median of 20.5 months (interquartile range, 13.25-33 months) of avoidance. Including those tolerating baked egg at presentation, 22.9% incorporated baked before unbaked egg. Sensitization did not delay tolerance but was linked to a higher risk of immediate hypersensitivity<span> during reintroduction. IgE-mediated symptoms were evident during reintroductions in sensitized patients but were absent in non-sensitized and untested patients. The overall phenotype switch rate from FPIES to IgE food allergy<span> was at least 9.2%. Concomitant IgE-mediated food allergy to other foods was more common among sensitized patients.</span></span></span></div></div><div><h3>Conclusions</h3><div>Our data suggest that testing for allergic sensitization to egg may help stratify patients with FPIES at risk for future IgE-mediated symptoms. Future prospective studies should evaluate the optimal timing and predictive value of skin testing in patients with FPIES and the utility of introducing baked egg in patients with egg FPIES.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2419-2428"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed Drug Eruption With Isotopic Response","authors":"Janet Choi BS ,&nbsp;Merav Koschitzky MD ,&nbsp;Hatice Zengin MD ,&nbsp;Bijal Amin MD ,&nbsp;Benedict Wu DO, PhD","doi":"10.1016/j.jaip.2025.06.024","DOIUrl":"10.1016/j.jaip.2025.06.024","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2494-2495.e2"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on “Neuropsychiatric events related to montelukast and pranlukast in adults with asthma and rhinitis: a 10-year nationwide population-based study”","authors":"Mi-Chi Su BS ,&nbsp;Jo-Ping Chang BS ,&nbsp;Su-Boon Yong MD, PhD ,&nbsp;Chin-Yuan Yii MD","doi":"10.1016/j.jaip.2025.05.065","DOIUrl":"10.1016/j.jaip.2025.05.065","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2534-2535"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145049954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time Course Until Tolerance for Food Protein–Induced Allergic Proctocolitis Varies by the Causal Food","authors":"Nagihan İskender MD ,&nbsp;Nefise Nezihe Uluç MD ,&nbsp;Ismail Ozanli MD ,&nbsp;Belkis Ipekci MD ,&nbsp;Taha Yasin Akın MD ,&nbsp;Mujde Tuba Cogurlu MD ,&nbsp;Aysen Uncuoğlu MD ,&nbsp;Nihal Uyar Aksu MD ,&nbsp;Sibel Balcı MD ,&nbsp;Isıl Eser Simsek MD ,&nbsp;Metin Aydoğan MD","doi":"10.1016/j.jaip.2025.06.010","DOIUrl":"10.1016/j.jaip.2025.06.010","url":null,"abstract":"<div><h3>Background</h3><div>For food protein–induced allergic proctocolitis (FPIAP), published information on the time until tolerance for each causal food and their combinations remains scarce.</div></div><div><h3>Objective</h3><div>To determine time until tolerance for individual causal foods, causal foods in combination, and factors affecting tolerance development.</div></div><div><h3>Methods</h3><div>Of the 91 patients diagnosed with FPIAP between March 2019 and March 2020, 84 patients with at least 3 years of follow-up were evaluated in this prospective cohort.</div></div><div><h3>Results</h3><div>The median age of the patients was 50 months at last evaluation (interquartile range [IQR]: 47-54 months), and 52.4% were male. The tolerance development rate was 36.6% in the first year, 88.9% in the second year, 96.4% in the third year, and 97.6% after the age of 3 years. The overall median tolerance development time was 15.5 (IQR: 12-22.5) months. For each causal food, cow’s milk (CM), beef, wheat, eggs, and nuts, median times until tolerance were 13 (IQR: 12-18), 13 (IQR: 12-18), 14 (IQR: 10.7-16), 16 (IQR: 12-24), and 24 (IQR: 22.5-36.5) months, respectively. In multiple food allergies (MFA), the presence of eggs significantly prolonged the time until tolerance, whereas the presence of beef did not. Multivariate regression analysis revealed that MFA presence (odds ratio [OR]: 12.11, 95% confidence interval [CI]: 1.23-118.12, <em>P</em> = .03), atopic dermatitis (AD) at onset (OR: 4.04, 95% CI: 1.15-14.25, <em>P</em> = .03), and the absence of a pet at home (OR: 0.23, 95% CI: 0.06-0.87, <em>P</em> = .03) were associated with delayed tolerance. The presence of IgE-mediated food allergy at onset was also associated with delayed tolerance (<em>P</em> = .02).</div></div><div><h3>Conclusions</h3><div>Tolerance development times to egg and nuts were longer than those to CM, beef, and wheat in FPIAP. Delayed tolerance appears to be due to the specific food combinations rather than multiple foods.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2429-2436.e1"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Effects of Polyphenolic Compounds on Allergic Rhinitis: A Systematic Review and Meta-Analysis","authors":"Yun-Ru Lai MD ,&nbsp;Yi-Hsueh Liao MD ,&nbsp;Li Huang MD ,&nbsp;Huynh Ba Phuong Linh MD, PhD ,&nbsp;Fasty Arum Utami MS ,&nbsp;Michele Miraglia Del Giudice MD ,&nbsp;Giorgio Ciprandi MD ,&nbsp;Yang-Ching Chen MD, PhD","doi":"10.1016/j.jaip.2025.06.032","DOIUrl":"10.1016/j.jaip.2025.06.032","url":null,"abstract":"<div><h3>Background</h3><div>Polyphenolic compounds (eg, catechins or quercetin) may reduce hypersensitivity and allergic symptoms, but clinical evidence remains inconsistent.</div></div><div><h3>Objective</h3><div>To evaluate the therapeutic potential of polyphenolic compounds for managing allergic rhinitis (AR).</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis of randomized controlled trials (RCTs) assessed the effects of polyphenolic compounds on AR symptoms and quality of life (QoL).</div></div><div><h3>Results</h3><div>Thirteen RCTs (823 participants) were included: 7 enrolling patients with seasonal AR and 6 with perennial AR. In seasonal AR, polyphenolic compounds significantly reduced total nasal symptom scores (standardized mean difference [SMD] = 0.75, <em>P</em> = .0001; <em>I</em>² = 52.8%), sneezing (SMD = 0.58, <em>P</em> = .0042; <em>I</em>² = 45.6%), and nasal itching (SMD = 0.54, <em>P</em> = .011; <em>I</em>² = 41.7%). In perennial AR, total nasal symptom scores improved, whereas individual symptoms were inconclusive. The combined analysis of seasonal and perennial AR, along with a sensitivity analysis excluding 2 outlier trials, yielded a more conservative and robust estimate, showing reductions in total nasal symptom scores (SMD = 0.73, <em>P</em> &lt; .0001; <em>I</em>² = 38.1%), nasal obstruction (SMD = 0.50, <em>P</em> = .0003; <em>I</em>² = 36.4%), and sneezing (SMD = 0.57, <em>P</em> &lt; .0001; <em>I</em>² = 25.7%). Overall certainty of evidence for key nasal symptom outcomes was low to very low due to inconsistency and risk of bias. Effects on QoL were not significant.</div></div><div><h3>Conclusion</h3><div>Polyphenolic compounds may serve as a complementary option for alleviating nasal symptoms in patients with AR, but findings should be interpreted cautiously. Future large-scale, rigorous RCTs are needed.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2475-2491.e16"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Diagnosis of Chronic Spontaneous Urticaria","authors":"","doi":"10.1016/j.jaip.2025.08.008","DOIUrl":"10.1016/j.jaip.2025.08.008","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Page 2251"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach.","authors":"Eileen Wang, William Henley, Désirée Larenas-Linnemann, Lakmini Bulathsinhala, Trung N Tran, Michael E Wechsler, Shawn D Aaron, Mona Al-Ahmad, Riyad Al-Lehebi, Alan Altraja, Peter Barker, Aaron Beastall, Andrey S Belevskiy, Celine Bergeron, Leif Bjermer, Unnur S Björnsdóttir, Sinthia Z Bosnic-Anticevich, Arnaud Bourdin, Guy G Brusselle, John Busby, Giorgio Walter Canonica, Victoria Carter, Kenneth R Chapman, Nicholas Chapman, George C Christoff, Borja G Cosio, Richard W Costello, James Fingleton, João A Ioa Fonseca, Mina Gaga, Peter G Gibson, Susanne Hansen, Liam G Heaney, Enrico Heffler, Mark Hew, Takahiko Horiguchi, Flavia Hoyte, Richard B Hubbard, Takashi Iwanaga, David J Jackson, Rohit Katial, Mariko Siyue Koh, Konstantinos Kostikas, Piotr Kuna, Sverre Lehmann, Lauri Lehtimäki, Renaud Louis, Dóra Lúdvíksdóttir, Njira Lugogo, Bassam Mahboub, Neil Martin, Jorge Máspero, Andrew N Menzies-Gow, Arjun Mohan, Ruth B Murray, Tatsuya Nagano, Nikolaos G Papadopoulos, Andriana I Papaioannou, Pujan H Patel, Luis Perez-de-Llano, Diahn-Warng Perng, Matthew J Peters, Paul E Pfeffer, Paulo Márcio Pitrez, Roy Alton Pleasants, Todor A Popov, Celeste M Porsbjerg, Francesca Puggioni, Anna Quinton, Chin Kook Rhee, Mohsen Sadatsafavi, Sundeep Salvi, Giulia Scioscia, Chau-Chyun Sheu, Concetta Sirena, Camille Taillé, Christian Taube, Carlos A Torres-Duque, Ming-Ju Tsai, Alf Tunsäter, Charlotte Suppli Ulrik, David B Price","doi":"10.1016/j.jaip.2025.08.021","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.08.021","url":null,"abstract":"<p><strong>Background: </strong>Asthma with low levels of T2-biomarkers is poorly understood.</p><p><strong>Objective: </strong>To characterize severe asthma phenotypes and compare pre- to post-biologic change in asthma outcomes along a gradient of T2-involvement.</p><p><strong>Methods: </strong>This was a registry-based, cohort study including data from 24 countries. Biomarker distribution (BEC, FeNO, IgE) was quantified pre-biologic initiation. Clusters were identified using a five-component Gaussian finite mixture model and phenotypically characterized. Change in asthma and healthcare utilization outcomes between 1-year pre- and post-biologic initiation were compared between clusters and by biologic class.</p><p><strong>Results: </strong>Amongst 3,675 patients Five biomarker clusters) were identified along a gradient of T2-involvement: Cluster A with the lowest T2-involvement (16.4%), Cluster B (20.4%), Cluster C (22.9%), Cluster D (30.3%), and cluster E with the highest T2-involvement (10.0%). In multivariable analysis, biologic use was associated with improved outcomes in all clusters but tended to be better at the higher end of the T2 spectrum. For example, patients in cluster C had a significantly greater increase in FEV₁ relative to cluster A (difference 0.16L [95% CI 0.08, 0.25]; p<0.001). The odds of uncontrolled asthma were approximately 0.6 for all clusters relative to cluster A.Overall, exacerbation rates were lower and greater improvements in lung function and asthma control were noted for anti-IL-5/5R (but not anti-IgE or anti-IL4Rα) for all clusters relative to cluster A.</p><p><strong>Conclusion: </strong>T2-targeting biologics have utility in the management of asthma with low T2 involvement, but more effective therapies are needed. Further research is warranted to identify specific pathogenic pathways at the lower end of the T2 spectrum that can be effectively targeted by biologics.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reported Demographics of Primary Immunodeficiency Diseases in the United States","authors":"Lavinia Ferrante di Ruffano PhD ,&nbsp;Emma Carr BA ,&nbsp;Mary Edwards MA ,&nbsp;Mick R. Arber MA ,&nbsp;Stephanie A. Grilo PhD ,&nbsp;Jennifer E. Posey MD, PhD ,&nbsp;Manar Abdalgani MBBS ,&nbsp;Jordan S. Orange MD, PhD","doi":"10.1016/j.jaip.2025.06.015","DOIUrl":"10.1016/j.jaip.2025.06.015","url":null,"abstract":"<div><h3>Background</h3><div>Primary immunodeficiency diseases (PIDDs) are rare genetic disorders impairing immunity. Studies evaluating diagnostic rates of PIDDs in historically marginalized US populations are limited.</div></div><div><h3>Objective</h3><div>To conduct a scoping review that identifies the extent of race and ethnicity reporting in US-based observational studies of people with PIDDs, and the demographic composition of study populations compared with the broader US population.</div></div><div><h3>Methods</h3><div>We conducted pragmatic searches of MEDLINE in April 2024 and ultimately included studies dating back 10 years. Results were screened and extracted against prespecified eligibility criteria by a single reviewer. Included data were compared with US census data using χ² tests.</div></div><div><h3>Results</h3><div>We identified 126 publications publishing observational PIDD studies that report patient characteristics, 62 of which (49%) reported race or ethnicity data. After grouping for data source and PIDD type to avoid overlapping studies, 25 publications were prioritized for extraction. Of these, seven were fully compliant with current Food and Drug Administration–recommended reporting guidelines. The populations of the extracted studies were not statistically representative of the broader US population, with overrepresentation of non-Hispanic White patients.</div></div><div><h3>Conclusions</h3><div>Primary immunodeficiency disease cohort and other studies inconsistently report demographic data on patient race and ethnicity according to current Food and Drug Administration recommendations. Efforts to improve understanding of the prevalence, characteristics, and diagnostic rates of PIDD in different US populations (as well as differences among study populations and overall US demographics) would likely be facilitated by a greater effort toward comprehensive demographic reporting.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2460-2474"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}